Goldman Sachs
EDIT icon

Goldman Sachs’s Editas Medicine EDIT Stock Holding History

Goldman Sachs’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Sell
558,577
-323,383
-37% -$684K ﹤0.01% 4859
2025
Q4 		$1.81M Buy
881,960
+423,684
+92% +$1.22M ﹤0.01% 4685
2025
Q3 		$1.59M Sell
458,276
-200,446
-30% -$559K ﹤0.01% 4677
2025
Q2 		$1.45M Buy
658,722
+91,218
+16% +$149K ﹤0.01% 4426
2025
Q1 		$658K Sell
567,504
-1,218,701
-68% -$1.79M ﹤0.01% 5006
2024
Q4 		$2.27M Buy
1,786,205
+619,011
+53% +$1.58M ﹤0.01% 4170
2024
Q3 		$3.98M Sell
1,167,194
-51,493
-4% -$224K ﹤0.01% 3554
2024
Q2 		$5.69M Sell
1,218,687
-182,245
-13% -$1.03M ﹤0.01% 3032
2024
Q1 		$10.4M Buy
1,400,932
+846,858
+153% +$7.04M ﹤0.01% 2434
2023
Q4 		$5.61M Buy
554,074
+108,935
+24% +$956K ﹤0.01% 3060
2023
Q3 		$3.47M Sell
445,139
-157,045
-26% -$1.35M ﹤0.01% 3317
2023
Q2 		$4.96M Sell
602,184
-103,872
-15% -$905K ﹤0.01% 3118
2023
Q1 		$5.12M Sell
706,056
-196,093
-22% -$1.74M ﹤0.01% 3034
2022
Q4 		$8M Sell
902,149
-213,574
-19% -$2.34M ﹤0.01% 2777
2022
Q3 		$13.7M Buy
1,115,723
+328,003
+42% +$5.11M ﹤0.01% 2209
2022
Q2 		$9.32M Buy
787,720
+152,171
+24% +$2.04M ﹤0.01% 2583
2022
Q1 		$12.1M Sell
635,549
-349,605
-35% -$6.5M ﹤0.01% 2495
2021
Q4 		$26.2M Sell
985,154
-401,275
-29% -$13.8M 0.01% 1885
2021
Q3 		$57M Buy
1,386,429
+583,116
+73% +$32M 0.01% 1193
2021
Q2 		$45.5M Sell
803,313
-104,666
-12% -$3.87M 0.01% 1348
2021
Q1 		$38.1M Sell
907,979
-115,713
-11% -$6.59M 0.01% 1386
2020
Q4 		$71.8M Buy
1,023,692
+34,134
+3% +$1.4M 0.02% 836
2020
Q3 		$27.8M Buy
989,558
+216,473
+28% +$7.05M 0.01% 1478
2020
Q2 		$22.9M Buy
773,085
+113,677
+17% +$2.97M 0.01% 1569
2020
Q1 		$13.1M Sell
659,408
-63,253
-9% -$1.6M ﹤0.01% 1859
2019
Q4 		$21.4M Buy
722,661
+47,243
+7% +$1.18M 0.01% 1793
2019
Q3 		$15.4M Sell
675,418
-123,840
-15% -$3.07M ﹤0.01% 1994
2019
Q2 		$19.8M Buy
799,258
+134,727
+20% +$3.22M 0.01% 1862
2019
Q1 		$16.2M Buy
664,531
+6,033
+0.9% +$137K ﹤0.01% 2044
2018
Q4 		$15M Buy
658,498
+196,422
+43% +$5.35M ﹤0.01% 2034
2018
Q3 		$14.7M Buy
462,076
+126,264
+38% +$4.08M ﹤0.01% 2147
2018
Q2 		$12M Sell
335,812
-7,112
-2% -$252K ﹤0.01% 2257
2018
Q1 		$11.4M Buy
342,924
+60,638
+21% +$2.16M ﹤0.01% 2232
2017
Q4 		$8.67M Sell
282,286
-55,800
-17% -$1.41M ﹤0.01% 2565
2017
Q3 		$8.12M Buy
338,086
+64,820
+24% +$1.23M ﹤0.01% 2740
2017
Q2 		$4.58M Buy
273,266
+238,707
+691% +$4.3M ﹤0.01% 3132
2017
Q1 		$771K Buy
34,559
+4,945
+17% +$102K ﹤0.01% 4621
2016
Q4 		$481K Sell
29,614
-13,917
-32% -$211K ﹤0.01% 5096
2016
Q3 		$586K Sell
43,531
-7,110
-14% -$146K ﹤0.01% 4895
2016
Q2 		$1.24M Sell
50,641
-19,000
-27% -$641K ﹤0.01% 4015
2016
Q1 		$2.4M Buy
+69,641
New +$1.83M ﹤0.01% 3309

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs's EDIT Position: Q1 2026 in Review

Goldman Sachs reduced its Editas Medicine (EDIT) stake by 37% in Q1 2026, selling an estimated $684K and leaving 558,577 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4859.

Goldman Sachs first reported a position in EDIT in Q1 2016 and has held it in 41 quarters since. The position peaked at $71.8M in Q4 2020. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Goldman Sachs held 558,577 shares of Editas Medicine worth $1.38M as of Q1 2026.
  • Goldman Sachs sold 323,383 Editas Medicine shares in Q1 2026, an estimated $684K.
  • Editas Medicine made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4859 holding.
  • Goldman Sachs first reported a position in Editas Medicine in Q1 2016 and has held it in 41 quarters since.
  • Goldman Sachs's Editas Medicine position peaked at $71.8M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.